Drug General Information
Drug ID
D05OQG
Former ID
DNC008644
Drug Name
ICARIIN
Drug Type
Small molecular drug
Indication Discovery agent Phase 3 [524514]
Structure
Download
2D MOL

3D MOL

Formula
C33H40O15
Canonical SMILES
CC1C(C(C(C(O1)OC2=C(OC3=C(C2=O)C(=CC(=C3CC=C(C)C)OC4C(C<br />(C(C(O4)CO)O)O)O)O)C5=CC=C(C=C5)OC)O)O)O
InChI
1S/C33H40O15/c1-13(2)5-10-17-19(45-33-28(42)26(40)23(37)20(12-34)46-33)11-18(35)21-24(38)31(48-32-27(41)25(39)22(36)14(3)44-32)29(47-30(17)21)15-6-8-16(43-4)9-7-15/h5-9,11,14,20,22-23,25-28,32-37,39-42H,10,12H2,1-4H3/t14-,20+,22-,23+,25+,26-,27+,28+,32?,33?/m0/s1
InChIKey
TZJALUIVHRYQQB-XGYHSCOOSA-N
CAS Number
CAS 489-32-7
PubChem Compound ID
Target and Pathway
Target(s) CGMP-specific 3',5'-cyclic phosphodiesterase Target Info Inhibitor [529676]
KEGG Pathway Purine metabolism
cGMP-PKG signaling pathway
NetPath Pathway TGF_beta_Receptor Signaling Pathway
Reactome cGMP effects
References
Ref 524514ClinicalTrials.gov (NCT01979133) Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders. U.S. National Institutes of Health.
Ref 529676J Nat Prod. 2008 Sep;71(9):1513-7. Epub 2008 Sep 9.Potent inhibition of human phosphodiesterase-5 by icariin derivatives.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.